厄贝沙坦对原发性高血压患者降血压和逆转心室肥厚的疗效观察

目的：观察血管紧张素Ⅱ受体拮抗剂对逆转原发性高血压（EH）患者左室肥厚（LVH）的作用。方法：对58例原发性高血压合并左室肥厚患者,服用厄贝沙坦每天150mg,疗程3个月,于治疗前及治疗后测的血压对比,同时彩色多普勒超声心动图测定参数对比。结果：58例原发性高血压合并左室肥厚患者服用厄贝沙坦治疗后血压下降明显,治疗前后差异有统计学意义（P〈0.01）,治疗前后对比,室间隔厚度（LVSD）、左室舒张末期内径（LVDD）、左室收缩末期内径（LVDS）、舒张末期左室后壁厚度（LVPWD）、左室射血分数（LVEF）、左室重量指数（LVMI）均比治疗前有显著改善（P〈0.01）。结论：厄贝沙坦治疗原发性高血压,除降压效果显著外,有逆转左心室肥厚,同时减少心肌重构的作用。

Therapeutic efficacy observation of erbesartan in lowering of blood pressure and reversal of ventricular hypertrophy in patients with essential hypertension

Objective： To observe the efficacy of angiotensin Ⅱ receptor antagonist in the reversal of left ventricular hypertrophy （LVH） in patients with essential hypertension （EH）. Methods： 58 patients with essential hypertension and left ventricular hypertrophy were given erbesartan 150 mg a day for 3 months. Blood pressure measurements and color Doppler echocardiography parameters before and after treatment were compared. Results： After treatment with erbesartan, blood pressure decreased significantly （P0.01） in the 58 patients with essential hypertension and left ventricular hypertrophy. Ventricular septal thickness （LVSD）, left ventricular end-diastolic diameter （LVDD）, left ventricular end systolic diameter （LVDS）, diastolicleft ventricular posterior wall thickness （LVPWD）, left ventricular ejection fraction （LVEF） and left ventricular mass index （LVMI） also showed significant improvement （P0.01）. Conclusion： In addition to significant antihypertension effect, erbesartan can also reverse left ventricular hypertrophy and reduce myocardial remodeling in patients with essential hypertension.